Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Manabu Hirai, MDPhD, Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Mizuki Aimoto, MD PhD, Erina Sakamoto, MD PhD

Blood (2015) 126 (23): 1688.

https://doi.org/10.1182/blood.V126.23.1688.1688

Published: 2015

Journal Articles

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

Manabu Hirai, MDPhD, Mizuki Aimoto, MD, Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Erina Sakamoto, MD PhD, Hirohisa Nakamae, Masayuki Hino, MD PhD

Blood (2014) 124 (21): 3260.

https://doi.org/10.1182/blood.V124.21.3260.3260

Published: 2014

Journal Articles

A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Manabu Hirai, MD, PHD, Takahiko Nakane, M.D., Ph.D., Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Mizuki Aimoto, M.D., Erina Sakamoto, MD, PHD, Hirohisa Nakamae, MD, PhD, Masayuki Hino, MD, PhD

Blood (2013) 122 (21): 1536.

https://doi.org/10.1182/blood.V122.21.1536.1536

Published: 2013

Journal Articles

Tolerated, Low-Dose Deferasirox: Successful Three Cases of Aplastic Anemia and 34 Cases of MDS

Manabu Hirai, MD, PHD, Ryousuke Yamamura, MD, PHD, Hirohisa Nakamae, MD, PhD, Yoshiki Terada, MD., PhD., Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Hiroyoshi Ichihara, MD, PHD, Erina Sakamoto, MD, PHD, Masayuki Hino

Blood (2012) 120 (21): 1187.

https://doi.org/10.1182/blood.V120.21.1187.1187

Published: 2012

Journal Articles

Feasibility of Cyclosporine and Short-Term Methotrexate for Graft-Vs.-Host disease Prophylaxis in T-Cell-Replete, Reduced-Intensity Allogeneic Bone Marrow Transplantation From Unrelated Donors.

Takahiko Nakane, MD, PhD, Hirohisa Nakamae, MD, PhD, Hideo Koh, MD, Mika Nakamae, MD, PhD, Yoshiki Hayashi, MD, Mitsutaka Nishimoto, MD, Takuro Yoshimura, MD, Eri Inoue, MD, Atsushi Inoue, MD, Ran Aimoto, MD, Mizuki Aimoto, MD, Yoshiki Terada, MD, PhD, Ki-Ryang Koh, MD, PhD, Takahisa Yamane, MD, PhD, Masayuki Hino, MD, PhD

Blood (2009) 114 (22): 4347.

https://doi.org/10.1182/blood.V114.22.4347.4347

Published: 2009

Journal Articles

Therapeutic Effect of CXCR3-Expressing Regulatory T Cells on Liver and Intestinal Damages in a Murine Acute GVHD Model.

Jun Yamanouchi, MD, PhD, Hitoshi Hasegawa, MD, PhD, Atsushi Inoue, MD, PhD, Masashi Kohno, MD, PhD, Hiroshi Fujiwara, MD, PhD, Takaaki Hato, MD, PhD, Masaki Yasukawa, MD, PhD

Blood (2007) 110 (11): 2161.

https://doi.org/10.1182/blood.V110.11.2161.2161

Published: 2007

NARROW

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Tolerated, Low-Dose Deferasirox: Successful Three Cases of Aplastic Anemia and 34 Cases of MDS

Feasibility of Cyclosporine and Short-Term Methotrexate for Graft-Vs.-Host disease Prophylaxis in T-Cell-Replete, Reduced-Intensity Allogeneic Bone Marrow Transplantation From Unrelated Donors.

Therapeutic Effect of CXCR3-Expressing Regulatory T Cells on Liver and Intestinal Damages in a Murine Acute GVHD Model.

Email alerts

ASH Publications

American Society of Hematology

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients

Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Tolerated, Low-Dose Deferasirox: Successful Three Cases of Aplastic Anemia and 34 Cases of MDS

Feasibility of Cyclosporine and Short-Term Methotrexate for Graft-Vs.-Host disease Prophylaxis in T-Cell-Replete, Reduced-Intensity Allogeneic Bone Marrow Transplantation From Unrelated Donors.

Therapeutic Effect of CXCR3-Expressing Regulatory T Cells on Liver and Intestinal Damages in a Murine Acute GVHD Model.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only